Absci Corporation (ABSI)
Nasdaq · Healthcare · Biotechnology
$11.53+4.16%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.0B
- 52-week range
- $2.24 – $12.06
- 52-week change
- +195.99%
- EPS (trailing)
- −$0.79
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $2.8M (−38.24%)
- Net income
- −$115M
- Operating margin
- −4297.1%
- Diluted EPS
- −$0.84
- Free cash flow
- −$94.0M
From the company’s annual report on SEC EDGAR.
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Headquarters: Vancouver, United States · 140 employees · absci.com